共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
3.
4.
Jianzhong Liu Shunqing Wang Ping Zhang Nasser Said-Al-Naief Suzanne M. Michalek Xu Feng 《The Journal of biological chemistry》2009,284(18):12512-12523
Lipopolysaccharide (LPS), a common bacteria-derived product, has long been
recognized as a key factor implicated in periodontal bone loss. However, the
precise cellular and molecular mechanisms by which LPS induces bone loss still
remains controversial. Here, we show that LPS inhibited osteoclastogenesis
from freshly isolated osteoclast precursors but stimulated osteoclast
formation from those pretreated with RANKL in vitro in tissue culture
dishes, bone slices, and a co-culture system containing osteoblasts,
indicating that RANKL-mediated lineage commitment is a prerequisite for
LPS-induced osteoclastogenesis. Moreover, the RANKL-mediated lineage
commitment is long term, irreversible, and TLR4-dependent. LPS exerts the dual
function primarily by modulating the expression of NFATc1, a master regulator
of osteoclastogenesis, in that it abolished RANKL-induced NFATc1 expression in
freshly isolated osteoclast precursors but stimulated its expression in
RANKL-pretreated cells. In addition, LPS prolonged osteoclast survival by
activating the Akt, NF-κB, and ERK pathways. Our current work has not
only unambiguously defined the role of LPS in osteoclastogenesis but also has
elucidated the molecular mechanism underlying its complex functions in
osteoclast formation and survival, thus laying a foundation for future
delineation of the precise mechanism of periodontal bone loss.LPS,2 a
common bacteria-derived product, has long been recognized as a key factor
implicated in the development of chronic periodontitis. LPS plays an important
role in periodontitis by initiating a local host response in gingival tissues
that involves recruitment of inflammatory cells, production of prostanoids and
cytokines, elaboration of lytic enzymes and activation of osteoclast formation
and function to induce bone loss
(1-3).Osteoclasts, the body''s sole bone-resorbing cells, are multinucleated giant
cells that differentiate from cells of hematopoietic lineage upon stimulation
by two critical factors: the macrophage/monocyte colony-forming factor (M-CSF)
and the receptor activator of NF-κB ligand (RANKL)
(4-6).
RANKL exerts its effects on osteoclast formation and function by binding to
its receptor, RANK (receptor activator of NF-κB) expressed on osteoclast
precursors and mature osteoclasts
(7-9).
RANKL also has a decoy receptor, osteoprotegerin, which inhibits RANKL action
by competing with RANK for binding RANKL
(10,
11).RANK is a member of the tumor necrosis factor receptor (TNFR) family
(12). Members of the TNFR
family lack intrinsic enzymatic activity, and hence they transduce
intracellular signals by recruiting various adaptor proteins including TNF
receptor-associated factors (TRAFs) through specific motifs in the cytoplasmic
domain (13,
14). It has been established
that RANK contains three functional TRAF-binding sites
(369PFQEP373, 559PVQEET564, and
604PVQEQG609) that, redundantly, play a role in
osteoclast formation and function
(15,
16). Collectively, through
these functional TRAF-binding motifs, RANK activates six major signaling
pathways, NF-κB, JNK, ERK, p38, NFATc1, and Akt, which play important
roles in osteoclast formation, function, and/or survival
(15,
17-19).
In particular, NFATc1 has been established as a master regulator of osteoclast
differentiation
(20-22).The involvement of osteoclasts in the pathogenesis of periodontal bone loss
is supported by observations that osteoclasts are physically present and
functionally involved in bone resorption in periodontal tissues
(23-27).
RANKL and RANK knockout mice develop osteopetrosis and show failure in tooth
eruption due to a lack of osteoclasts
(24,
25,
28). Moreover,
op/op mice, in which a mutation in the coding region of the
M-CSF gene generates a stop codon that leads to premature termination of
translation of M-CSF mRNA, also show osteopetrosis and failure in tooth
eruption due to a defect in osteoclast development
(26,
27).Whereas the role of osteoclasts in periodontal disease associated alveolar
bone destruction has been well established, the precise role of LPS in
osteoclastogenesis still remains controversial. The vast majority of the
previous studies demonstrated that LPS stimulates osteoclastogenesis. This is
consistent with the role that LPS, a well recognized pathogenic factor in
periodontitis, presumably plays in periodontal bone loss
(29-33).
However, two previous studies demonstrated, surprisingly, that LPS plays
bifunctional roles in osteoclastogenesis in that although it inhibits
osteoclast formation from normal osteoclast precursors, it reverses to promote
osteoclastogenesis from osteoclast precursors pretreated with RANKL
(34,
35). Given that this finding
is inconsistent with the presumed role of LPS as a pathogenic factor in
periodontal bone loss and lacks careful and further validation, the prevalent
view is still that LPS stimulates osteoclastogenesis
(1-3).
Importantly, if LPS indeed has a dual function in osteoclastogenesis, the
molecular mechanism by which LPS exerts a dual effect on osteoclastogenesis
need to be further elucidated.In the present work, using various in vitro assays, we have
demonstrated independently that LPS inhibits osteoclastogenesis from normal
osteoclast precursors but promotes the development of osteoclasts from
RANKL-pretreated cells in tissue culture dishes and bone slices in single-cell
and co-culture settings, confirming the two previous observations that LPS
play a bifunctional role in osteoclastogenesis
(34,
35). Moreover, we have further
shown that the RANKL-mediated lineage commitment is long term and irreversible
in LPS-mediated osteoclastogenesis. More importantly, we have revealed that
LPS inhibits osteoclastogenesis by suppressing NFATc1 expression and JNK
activation while it prolongs osteoclast survival by activating the Akt,
NF-κB, and ERK pathways. These studies have not only unambiguously and
precisely defined the role of LPS in osteoclastogenesis but, more importantly,
may also lead to a paradigm shift in future investigation of the molecular
mechanism of periodontal bone loss. 相似文献
5.
6.
7.
Ruben K. Dagda Salvatore J. Cherra III Scott M. Kulich Anurag Tandon David Park Charleen T. Chu 《The Journal of biological chemistry》2009,284(20):13843-13855
Mitochondrial dysregulation is strongly implicated in Parkinson disease.
Mutations in PTEN-induced kinase 1 (PINK1) are associated with familial
parkinsonism and neuropsychiatric disorders. Although overexpressed PINK1 is
neuroprotective, less is known about neuronal responses to loss of PINK1
function. We found that stable knockdown of PINK1 induced mitochondrial
fragmentation and autophagy in SH-SY5Y cells, which was reversed by the
reintroduction of an RNA interference (RNAi)-resistant plasmid for PINK1.
Moreover, stable or transient overexpression of wild-type PINK1 increased
mitochondrial interconnectivity and suppressed toxin-induced
autophagy/mitophagy. Mitochondrial oxidant production played an essential role
in triggering mitochondrial fragmentation and autophagy in PINK1 shRNA lines.
Autophagy/mitophagy served a protective role in limiting cell death, and
overexpressing Parkin further enhanced this protective mitophagic response.
The dominant negative Drp1 mutant inhibited both fission and mitophagy in
PINK1-deficient cells. Interestingly, RNAi knockdown of autophagy proteins
Atg7 and LC3/Atg8 also decreased mitochondrial fragmentation without affecting
oxidative stress, suggesting active involvement of autophagy in morphologic
remodeling of mitochondria for clearance. To summarize, loss of PINK1 function
elicits oxidative stress and mitochondrial turnover coordinated by the
autophagic and fission/fusion machineries. Furthermore, PINK1 and Parkin may
cooperate through different mechanisms to maintain mitochondrial
homeostasis.Parkinson disease is an age-related neurodegenerative disease that affects
∼1% of the population worldwide. The causes of sporadic cases are unknown,
although mitochondrial or oxidative toxins such as
1-methyl-4-phenylpyridinium, 6-hydroxydopamine
(6-OHDA),3 and
rotenone reproduce features of the disease in animal and cell culture models
(1). Abnormalities in
mitochondrial respiration and increased oxidative stress are observed in cells
and tissues from parkinsonian patients
(2,
3), which also exhibit
increased mitochondrial autophagy
(4). Furthermore, mutations in
parkinsonian genes affect oxidative stress response pathways and mitochondrial
homeostasis (5). Thus,
disruption of mitochondrial homeostasis represents a major factor implicated
in the pathogenesis of sporadic and inherited parkinsonian disorders (PD).The PARK6 locus involved in autosomal recessive and early-onset PD
encodes for PTEN-induced kinase 1 (PINK1)
(6,
7). PINK1 is a cytosolic and
mitochondrially localized 581-amino acid serine/threonine kinase that
possesses an N-terminal mitochondrial targeting sequence
(6,
8). The primary sequence also
includes a putative transmembrane domain important for orientation of the
PINK1 domain (8), a conserved
kinase domain homologous to calcium calmodulin kinases, and a C-terminal
domain that regulates autophosphorylation activity
(9,
10). Overexpression of
wild-type PINK1, but not its PD-associated mutants, protects against several
toxic insults in neuronal cells
(6,
11,
12). Mitochondrial targeting
is necessary for some (13) but
not all of the neuroprotective effects of PINK1
(14), implicating involvement
of cytoplasmic targets that modulate mitochondrial pathobiology
(8). PINK1 catalytic activity
is necessary for its neuroprotective role, because a kinase-deficient K219M
substitution in the ATP binding pocket of PINK1 abrogates its ability to
protect neurons (14). Although
PINK1 mutations do not seem to impair mitochondrial targeting, PD-associated
mutations differentially destabilize the protein, resulting in loss of
neuroprotective activities
(13,
15).Recent studies indicate that PINK1 and Parkin interact genetically
(3,
16-18)
to prevent oxidative stress
(19,
20) and regulate mitochondrial
morphology (21). Primary cells
derived from PINK1 mutant patients exhibit mitochondrial fragmentation with
disorganized cristae, recapitulated by RNA interference studies in HeLa cells
(3).Mitochondria are degraded by macroautophagy, a process involving
sequestration of cytoplasmic cargo into membranous autophagic vacuoles (AVs)
for delivery to lysosomes (22,
23). Interestingly,
mitochondrial fission accompanies autophagic neurodegeneration elicited by the
PD neurotoxin 6-OHDA (24,
25). Moreover, mitochondrial
fragmentation and increased autophagy are observed in neurodegenerative
diseases including Alzheimer and Parkinson diseases
(4,
26-28).
Although inclusion of mitochondria in autophagosomes was once believed to be a
random process, as observed during starvation, studies involving hypoxia,
mitochondrial damage, apoptotic stimuli, or limiting amounts of aerobic
substrates in facultative anaerobes support the concept of selective
mitochondrial autophagy (mitophagy)
(29,
30). In particular,
mitochondrially localized kinases may play an important role in models
involving oxidative mitochondrial injury
(25,
31,
32).Autophagy is involved in the clearance of protein aggregates
(33-35)
and normal regulation of axonal-synaptic morphology
(36). Chronic disruption of
lysosomal function results in accumulation of subtly impaired mitochondria
with decreased calcium buffering capacity
(37), implicating an important
role for autophagy in mitochondrial homeostasis
(37,
38). Recently, Parkin, which
complements the effects of PINK1 deficiency on mitochondrial morphology
(3), was found to promote
autophagy of depolarized mitochondria
(39). Conversely, Beclin
1-independent autophagy/mitophagy contributes to cell death elicited by the PD
toxins 1-methyl-4-phenylpyridinium and 6-OHDA
(25,
28,
31,
32), causing neurite
retraction in cells expressing a PD-linked mutation in leucine-rich repeat
kinase 2 (40). Whereas
properly regulated autophagy plays a homeostatic and neuroprotective role,
excessive or incomplete autophagy creates a condition of “autophagic
stress” that can contribute to neurodegeneration
(28).As mitochondrial fragmentation
(3) and increased mitochondrial
autophagy (4) have been
described in human cells or tissues of PD patients, we investigated whether or
not the engineered loss of PINK1 function could recapitulate these
observations in human neuronal cells (SH-SY5Y). Stable knockdown of endogenous
PINK1 gave rise to mitochondrial fragmentation and increased autophagy and
mitophagy, whereas stable or transient overexpression of PINK1 had the
opposite effect. Autophagy/mitophagy was dependent upon increased
mitochondrial oxidant production and activation of fission. The data indicate
that PINK1 is important for the maintenance of mitochondrial networks,
suggesting that coordinated regulation of mitochondrial dynamics and autophagy
limits cell death associated with loss of PINK1 function. 相似文献
8.
As obligate intracellular parasites, viruses exploit diverse cellular
signaling machineries, including the mitogen-activated protein-kinase pathway,
during their infections. We have demonstrated previously that the open reading
frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus interacts with p90
ribosomal S6 kinases (RSKs) and strongly stimulates their kinase activities
(Kuang, E., Tang, Q., Maul, G. G., and Zhu, F.
(2008) J. Virol. 82
,1838
-1850). Here, we define the
mechanism by which ORF45 activates RSKs. We demonstrated that binding of ORF45
to RSK increases the association of extracellular signal-regulated kinase
(ERK) with RSK, such that ORF45, RSK, and ERK formed high molecular mass
protein complexes. We further demonstrated that the complexes shielded active
pERK and pRSK from dephosphorylation. As a result, the complex-associated RSK
and ERK were activated and sustained at high levels. Finally, we provide
evidence that this mechanism contributes to the sustained activation of ERK
and RSK in Kaposi sarcoma-associated herpesvirus lytic replication.The extracellular signal-regulated kinase
(ERK)2
mitogen-activated protein kinase (MAPK) signaling pathway has been implicated
in diverse cellular physiological processes including proliferation, survival,
growth, differentiation, and motility
(1-4)
and is also exploited by a variety of viruses such as Kaposi
sarcoma-associated herpesvirus (KSHV), human cytomegalovirus, human
immunodeficiency virus, respiratory syncytial virus, hepatitis B virus,
coxsackie, vaccinia, coronavirus, and influenza virus
(5-17).
The MAPK kinases relay the extracellular signaling through sequential
phosphorylation to an array of cytoplasmic and nuclear substrates to elicit
specific responses (1,
2,
18). Phosphorylation of MAPK
is reversible. The kinetics of deactivation or duration of signaling dictates
diverse biological outcomes
(19,
20). For example, sustained
but not transient activation of ERK signaling induces the differentiation of
PC12 cells into sympathetic-like neurons and transformation of NIH3T3 cells
(20-22).
During viral infection, a unique biphasic ERK activation has been observed for
some viruses (an early transient activation triggered by viral binding or
entry and a late sustained activation correlated with viral gene expression),
but the responsible viral factors and underlying mechanism for the sustained
ERK activation remain largely unknown
(5,
8,
13,
23).The p90 ribosomal S6 kinases (RSKs) are a family of serine/threonine
kinases that lie at the terminus of the ERK pathway
(1,
24-26).
In mammals, four isoforms are known, RSK1 to RSK4. Each one has two
catalytically functional kinase domains, the N-terminal kinase domain (NTKD)
and C-terminal kinase domain (CTKD) as well as a linker region between the
two. The NTKD is responsible for phosphorylation of exogenous substrates, and
the CTKD and linker region regulate RSK activation
(1,
24,
25). In quiescent cells ERK
binds to the docking site in the C terminus of RSK
(27-29).
Upon mitogen stimulation, ERK is activated by its upstream MAPK/ERK kinase
(MEK). The active ERK phosphorylates Thr-359/Ser-363 of RSK in the linker
region (amino acid numbers refer to human RSK1) and Thr-573 in the CTKD
activation loop. The activated CTKD then phosphorylates Ser-380 in the linker
region, creating a docking site for 3-phosphoinositide-dependent protein
kinase-1. The 3-phosphoinositide-dependent protein kinase-1 phosphorylates
Ser-221 of RSK in the activation loop and activates the NTKD. The activated
NTKD autophosphorylates the serine residue near the ERK docking site, causing
a transient dissociation of active ERK from RSK
(25,
26,
28). The stimulation of
quiescent cells by a mitogen such as epidermal growth factor or a phorbol
ester such as 12-O-tetradecanoylphorbol-13-acetate (TPA) usually
results in a transient RSK activation that lasts less than 30 min. RSKs have
been implicated in regulating cell survival, growth, and proliferation.
Mutation or aberrant expression of RSK has been implicated in several human
diseases including Coffin-Lowry syndrome and prostate and breast cancers
(1,
24,
25,
30-32).KSHV is a human DNA tumor virus etiologically linked to Kaposi sarcoma,
primary effusion lymphoma, and a subset of multicentric Castleman disease
(33,
34). Infection and
reactivation of KSHV activate multiple MAPK pathways
(6,
12,
35). Noticeably, the ERK/RSK
activation is sustained late during KSHV primary infection and reactivation
from latency (5,
6,
12,
23), but the mechanism of the
sustained ERK/RSK activation is unclear. Recently, we demonstrated that ORF45,
an immediate early and also virion tegument protein of KSHV, interacts with
RSK1 and RSK2 and strongly stimulates their kinase activities
(23). We also demonstrated
that the activation of RSK plays an essential role in KSHV lytic replication
(23). In the present study we
determined the mechanism of ORF45-induced sustained ERK/RSK activation. We
found that ORF45 increases the association of RSK with ERK and protects them
from dephosphorylation, causing sustained activation of both ERK and RSK. 相似文献
9.
Brooke K. McMichael Robert B. Wysolmerski Beth S. Lee 《The Journal of biological chemistry》2009,284(18):12266-12275
The nonmuscle myosin IIA heavy chain (Myh9) is strongly associated with
adhesion structures of osteoclasts. In this study, we demonstrate that during
osteoclastogenesis, myosin IIA heavy chain levels are temporarily suppressed,
an event that stimulates the onset of cell fusion. This suppression is not
mediated by changes in mRNA or translational levels but instead is due to a
temporary increase in the rate of myosin IIA degradation. Intracellular
activity of cathepsin B is significantly enhanced at the onset of osteoclast
precursor fusion, and specific inhibition of its activity prevents myosin IIA
degradation. Further, treatment of normal cells with cathepsin B inhibitors
during the differentiation process reduces cell fusion and bone resorption
capacity, whereas overexpression of cathepsin B enhances fusion. Ongoing
suppression of the myosin IIA heavy chain via RNA interference results in
formation of large osteoclasts with significantly increased numbers of nuclei,
whereas overexpression of myosin IIA results in less osteoclast fusion.
Increased multinucleation caused by myosin IIA suppression does not require
RANKL. Further, knockdown of myosin IIA enhances cell spreading and lessens
motility. These data taken together strongly suggest that base-line expression
of nonmuscle myosin IIA inhibits osteoclast precursor fusion and that a
temporary, cathepsin B-mediated decrease in myosin IIA levels triggers
precursor fusion during osteoclastogenesis.The final stages of osteoclastogenesis involve fusion of differentiated
precursors from the monocyte/macrophage lineage
(1). Although the membrane
structural components regulating preosteoclast fusion are not well understood,
in recent years a number of candidate cell surface molecules have been
implicated, including receptors CD44
(2,
3), CD47 and its ligand
macrophage fusion receptor (also known as signal regulatory protein α)
(4–6),
the purinergic receptor P2X7
(7), and the disintegrin and
metalloproteinase ADAM8 (8). A
recently identified receptor, the dendritic cell-specific transmembrane
protein, is essential for osteoclast fusion both in vitro and in
vivo (9,
10). More recently, the d2
subunit of proton-translocating vacuolar proton-translocating ATPases, a
membrane subunit isoform expressed predominantly in osteoclasts, similarly was
demonstrated to be required for fusion in vitro and in vivo
(11). However, elucidation of
the mechanisms by which these molecules may mediate cell fusion has proved to
be difficult.The mammalian class II myosin family consists of distinct isoforms
expressed in skeletal, smooth, and cardiac muscle, as well as three nonmuscle
forms designated IIA, IIB, and IIC
(12–14).
Although all class II molecules are composed of two heavy chains, two
essential light chains, and two regulatory chains, their unique activities are
a function of their particular heavy chain isoforms. Although the nonmuscle
heavy chain isoforms share extensive structural homology, they have been shown
to demonstrate distinct patterns of expression
(15–18),
enzyme kinetics and activation
(12,
19–21),
and cellular function
(22–24).
Knock-out of either myosin IIA or IIB results in embryonic lethality, although
death derives from defects unique to each isoform
(25,
26). In vitro, myosin
IIA, a target of Rho kinase, has been shown to be involved in a wide variety
of cellular functions, including cytokinesis, cell contractility, and adhesion
and motility.The actin cytoskeleton of osteoclasts possesses features unlike those of
most mammalian cell types. First, osteoclasts do not possess stress fibers but
instead form a meshwork of fine actin filaments throughout the cell
(27–29).
Osteoclasts express unusual attachment structures typified by the podosome, a
form of adhesion structure most typically present in cells of the
monocyte/macrophage lineage, dendritic cells, and smooth muscle cells.
Podosomes are integrin-based cell-matrix contact structures that are notable
for the presence of a short (0.5–1.0 μm) F-actin core surrounded by a
ring of adaptor proteins, kinases, small GTPases, and regulators of
endocytosis (30,
31). When cultured on glass,
mature osteoclasts generate a belt of podosomes at the cell periphery.
However, when cultured on bone, osteoclasts form a dense ring of podosome-like
structures that is usually internal to the cell margins
(32). This region, termed the
sealing zone, surrounds a specialized membrane domain termed the ruffled
border, from which protons and proteases are secreted to induce resorption of
bone (1). We previously
demonstrated that myosins IIA and IIB localize to distinct subcellular regions
within osteoclasts, with
MyoIIA2 strongly
segregating to both podosomes and the actin ring of the sealing zone
(28). Because of this
distribution into osteoclast adhesion structures and findings in other cells
showing MyoIIA to be associated with dynamic Rho-kinase-dependent functions,
such as adhesion and locomotion, we hypothesized that MyoIIA may play a vital
role in cell motility and the bone resorption function. In this study, we
examined cellular expression of MyoIIA during osteoclastogenesis and, along
with RNA interference-mediated suppression of the protein, have confirmed its
role in cell spreading, motility, and sealing zone formation. However, this
study also unexpectedly revealed a role for MyoIIA in regulating preosteoclast
fusion during osteoclastogenesis. 相似文献
10.
11.
Susan R. Wilson Christoph Peters Paul Saftig Dieter Br?mme 《The Journal of biological chemistry》2009,284(4):2584-2592
Cathepsin K is responsible for the degradation of type I collagen in
osteoclast-mediated bone resorption. Collagen fragments are known to be
biologically active in a number of cell types. Here, we investigate their
potential to regulate osteoclast activity. Mature murine osteoclasts were
seeded on type I collagen for actin ring assays or dentine discs for
resorption assays. Cells were treated with cathepsins K-, L-, or
MMP-1-predigested type I collagen or soluble bone fragments for 24 h. The
presence of actin rings was determined fluorescently by staining for actin. We
found that the percentage of osteoclasts displaying actin rings and the area
of resorbed dentine decreased significantly on addition of cathepsin
K-digested type I collagen or bone fragments, but not with cathepsin L or
MMP-1 digests. Counterintuitively, actin ring formation was found to decrease
in the presence of the cysteine proteinase inhibitor LHVS and in cathepsin
K-deficient osteoclasts. However, cathepsin L deficiency or the general MMP
inhibitor GM6001 had no effect on the presence of actin rings. Predigestion of
the collagen matrix with cathepsin K, but not by cathepsin L or MMP-1 resulted
in an increased actin ring presence in cathepsin K-deficient osteoclasts.
These studies suggest that cathepsin K interaction with type I collagen is
required for 1) the release of cryptic Arg-Gly-Asp motifs during the initial
attachment of osteoclasts and 2) termination of resorption via the creation of
autocrine signals originating from type I collagen degradation.Osteoclasts are monocyte-macrophage lineage-derived, large multinucleated
cells. They are the major bone resorbing cells, essential for bone turnover
and development. Active osteoclasts display characteristic membranes,
including the ruffled border, attachment zone, and the basolateral secretory
membrane. After attachment to bone, the ruffled border secretes enzymes and
protons enabling the solubilization and digestion of the bone matrix.
Osteoclasts express many proteases including cathepsins and matrix
metalloproteases
(MMPs)2 (for review
see Refs.
1-3).
However, it is the general consensus that cathepsin K (catK) is the major
bone-degrading enzyme
(4-7).Rapid cytoskeletal reorganization is essential for osteoclast function and
formation of the specialized membranes. Bone resorption occurs within the
sealing zone, which is formed by an actin ring structure. This can be
identified as a solid circular belt like formation and consists of an actin
filament core surrounded by actin-binding proteins such as talin,
α-actinin, and vinculin, which link matrix-recognizing integrins to the
cytoskeleton (8). The ruffled
border is contained within this structure. The actin ring is initiated by the
formation of podosomes, which represent dot-like actin structures of small
F-actin containing columns surrounded by proteins also found in focal adhesion
such as vinculin and paxillin
(9). It was previously thought
that the sealing zone was formed by the fusion of podosomes after the
osteoclast becomes activated
(10,
11), but it has since been
demonstrated that podosomes and the sealing zone are distinct structures
(12,
13). It should be noted that
bone resorption only occurs when the sealing zone is formed and the actin ring
is present (14).Osteoclasts bind and interact with the bone surface through specific
integrin receptors. The most abundant integrin present in osteoclasts is the
αvß3 receptor also known as the vitronectin receptor
(15,
16). This receptor attaches to
RGD sequence containing components of the bone matrix, e.g.
vitronectin, osteopontin, and type I collagen
(17-19).
This interaction enables the formation and regulation of the actin ring and
therefore osteoclast activity
(20-22).
It has previously been shown that soluble RGD containing peptides added to
cell supernatant are capable of inhibiting osteoclast binding and bone
resorption (18,
22-24).This study investigates the effect of collagen degradation fragments on
osteoclast activity. Soluble type I collagen and the bone powder of murine
long bones were subjected to digestion reactions by the cysteine proteases,
catK and catL, and the interstitial collagenase, MMP-1. The effect of these
degradation products on osteoclasts was investigated by monitoring actin ring
and resorption pit formation. We further investigated the role of cathepsins
using catK- and catL-deficient mice. Finally, we looked in more detail at the
effect of collagen, as a cell adhesion matrix, on osteoclast activity. 相似文献
12.
13.
14.
15.
Mikael K. Schnizler Katrin Schnizler Xiang-ming Zha Duane D. Hall John A. Wemmie Johannes W. Hell Michael J. Welsh 《The Journal of biological chemistry》2009,284(5):2697-2705
The acid-sensing ion channel 1a (ASIC1a) is widely expressed in central and
peripheral neurons where it generates transient cation currents when
extracellular pH falls. ASIC1a confers pH-dependent modulation on postsynaptic
dendritic spines and has critical effects in neurological diseases associated
with a reduced pH. However, knowledge of the proteins that interact with
ASIC1a and influence its function is limited. Here, we show that
α-actinin, which links membrane proteins to the actin cytoskeleton,
associates with ASIC1a in brain and in cultured cells. The interaction
depended on an α-actinin-binding site in the ASIC1a C terminus that was
specific for ASIC1a versus other ASICs and for α-actinin-1 and
-4. Co-expressing α-actinin-4 altered ASIC1a current density, pH
sensitivity, desensitization rate, and recovery from desensitization.
Moreover, reducing α-actinin expression altered acid-activated currents
in hippocampal neurons. These findings suggest that α-actinins may link
ASIC1a to a macromolecular complex in the postsynaptic membrane where it
regulates ASIC1a activity.Acid-sensing ion channels
(ASICs)2 are
H+-gated members of the DEG/ENaC family
(1–3).
Members of this family contain cytosolic N and C termini, two transmembrane
domains, and a large cysteine-rich extracellular domain. ASIC subunits combine
as homo- or heterotrimers to form cation channels that are widely expressed in
the central and peripheral nervous systems
(1–4).
In mammals, four genes encode ASICs, and two subunits, ASIC1 and ASIC2, have
two splice forms, a and b. Central nervous system neurons express ASIC1a,
ASIC2a, and ASIC2b
(5–7).
Homomeric ASIC1a channels are activated when extracellular pH drops below 7.2,
and half-maximal activation occurs at pH 6.5–6.8
(8–10).
These channels desensitize in the continued presence of a low extracellular
pH, and they can conduct Ca2+
(9,
11–13).
ASIC1a is required for acid-evoked currents in central nervous system neurons;
disrupting the gene encoding ASIC1a eliminates H+-gated currents
unless extracellular pH is reduced below pH 5.0
(5,
7).Previous studies found ASIC1a enriched in synaptosomal membrane fractions
and present in dendritic spines, the site of excitatory synapses
(5,
14,
15). Consistent with this
localization, ASIC1a null mice manifested deficits in hippocampal
long term potentiation, learning, and memory, which suggested that ASIC1a is
required for normal synaptic plasticity
(5,
16). ASICs might be activated
during neurotransmission when synaptic vesicles empty their acidic contents
into the synaptic cleft or when neuronal activity lowers extracellular pH
(17–19).
Ion channels, including those at the synapse often interact with multiple
proteins in a macromolecular complex that incorporates regulators of their
function (20,
21). For ASIC1a, only a few
interacting proteins have been identified. Earlier work indicated that ASIC1a
interacts with another postsynaptic scaffolding protein, PICK1
(15,
22,
23). ASIC1a also has been
reported to interact with annexin II light chain p11 through its cytosolic N
terminus to increase cell surface expression
(24) and with
Ca2+/calmodulin-dependent protein kinase II to phosphorylate the
channel (25). However, whether
ASIC1a interacts with additional proteins and with the cytoskeleton remain
unknown. Moreover, it is not known whether such interactions alter ASIC1a
function.In analyzing the ASIC1a amino acid sequence, we identified cytosolic
residues that might bind α-actinins. α-Actinins cluster membrane
proteins and signaling molecules into macromolecular complexes and link
membrane proteins to the actincytoskeleton (for review, Ref.
26). Four genes encode
α-actinin-1, -2, -3, and -4 isoforms. α-Actinins contain an
N-terminal head domain that binds F-actin, a C-terminal region containing two
EF-hand motifs, and a central rod domain containing four spectrin-like motifs
(26–28).
The C-terminal portion of the rod segment appears to be crucial for binding to
membrane proteins. The α-actinins assemble into antiparallel homodimers
through interactions in their rod domain. α-Actinins-1, -2, and -4 are
enriched in dendritic spines, concentrating at the postsynaptic membrane
(29–35).
In the postsynaptic membrane of excitatory synapses, α-actinin connects
the NMDA receptor to the actin cytoskeleton, and this interaction is key for
Ca2+-dependent inhibition of NMDA receptors
(36–38).
α-Actinins can also regulate the membrane trafficking and function of
several cation channels, including L-type Ca2+ channels,
K+ channels, and TRP channels
(39–41).To better understand the function of ASIC1a channels in macromolecular
complexes, we asked if ASIC1a associates with α-actinins. We were
interested in the α-actinins because they and ASIC1a, both, are present
in dendritic spines, ASIC1a contains a potential α-actinin binding
sequence, and the related epithelial Na+ channel (ENaC) interacts
with the cytoskeleton (42,
43). Therefore, we
hypothesized that α-actinin interacts structurally and functionally with
ASIC1a. 相似文献
16.
17.
Kuen-Feng Chen Pei-Yen Yeh Chiun Hsu Chih-Hung Hsu Yen-Shen Lu Hsing-Pang Hsieh Pei-Jer Chen Ann-Lii Cheng 《The Journal of biological chemistry》2009,284(17):11121-11133
Hepatocellular carcinoma (HCC) is one of the most common and aggressive
human malignancies. Recombinant tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is a promising anti-tumor agent. However,
many HCC cells show resistance to TRAIL-induced apoptosis. In this study, we
showed that bortezomib, a proteasome inhibitor, overcame TRAIL resistance in
HCC cells, including Huh-7, Hep3B, and Sk-Hep1. The combination of bortezomib
and TRAIL restored the sensitivity of HCC cells to TRAIL-induced apoptosis.
Comparing the molecular change in HCC cells treated with these agents, we
found that down-regulation of phospho-Akt (P-Akt) played a key role in
mediating TRAIL sensitization of bortezomib. The first evidence was that
bortezomib down-regulated P-Akt in a dose- and time-dependent manner in
TRAIL-treated HCC cells. Second, , a PI3K inhibitor, also sensitized
resistant HCC cells to TRAIL-induced apoptosis. Third, knocking down Akt1 by
small interference RNA also enhanced TRAIL-induced apoptosis in Huh-7 cells.
Finally, ectopic expression of mutant Akt (constitutive active) in HCC cells
abolished TRAIL sensitization effect of bortezomib. Moreover, okadaic acid, a
protein phosphatase 2A (PP2A) inhibitor, reversed down-regulation of P-Akt in
bortezomib-treated cells, and PP2A knockdown by small interference RNA also
reduced apoptosis induced by the combination of TRAIL and bortezomib,
indicating that PP2A may be important in mediating the effect of bortezomib on
TRAIL sensitization. Together, bortezomib overcame TRAIL resistance at
clinically achievable concentrations in hepatocellular carcinoma cells, and
this effect is mediated at least partly via inhibition of the PI3K/Akt
pathway.Hepatocellular carcinoma
(HCC) LY2940022 is currently
the fifth most common solid tumor worldwide and the fourth leading cause of
cancer-related death. To date, surgery is still the only curative treatment
but is only feasible in a small portion of patients
(1). Drug treatment is the
major therapy for patients with advanced stage disease. Unfortunately, the
response rate to traditional chemotherapy for HCC patients is unsatisfactory
(1). Novel pharmacological
therapy is urgently needed for patients with advanced HCC. In this regard, the
approval of sorafenib might open a new era of molecularly targeted therapy in
the treatment of HCC patients.Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a
type II transmembrane protein and a member of the TNF family, is a promising
anti-tumor agent under clinical investigation
(2). TRAIL functions by
engaging its receptors expressed on the surface of target cells. Five
receptors specific for TRAIL have been identified, including DR4/TRAIL-R1,
DR5/TRAIL-R2, DcR1, DcR2, and osteoprotegerin. Among TRAIL receptors, only DR4
and DR5 contain an effective death domain that is essential to formation of
death-inducing signaling complex (DISC), a critical step for TRAIL-induced
apoptosis. Notably, the trimerization of the death domains recruits an adaptor
molecule, Fas-associated protein with death domain (FADD), which subsequently
recruits and activates caspase-8. In type I cells, activation of caspase-8 is
sufficient to activate caspase-3 to induce apoptosis; however, in another type
of cells (type II), the intrinsic mitochondrial pathway is essential for
apoptosis characterized by cleavage of Bid and release of cytochrome
c from mitochondria, which subsequently activates caspase-9 and
caspase-3 (3).Although TRAIL induces apoptosis in malignant cells but sparing normal
cells, some tumor cells are resistant to TRAIL-induced apoptosis. Mechanisms
responsible for the resistance include receptors and intracellular resistance.
Although the cell surface expression of DR4 or DR5 is absolutely required for
TRAIL-induced apoptosis, tumor cells expressing these death receptors are not
always sensitive to TRAIL due to intracellular mechanisms. For example, the
cellular FLICE-inhibitory protein (c-FLIP), a homologue to caspase-8 but
without protease activity, has been linked to TRAIL resistance in several
studies (4,
5). In addition, inactivation
of Bax, a proapoptotic Bcl-2 family protein, resulted in resistance to TRAIL
in MMR-deficient tumors (6,
7), and reintroduction of Bax
into Bax-deficient cells restored TRAIL sensitivity
(8), indicating that the Bcl-2
family plays a critical role in intracellular mechanisms for resistance of
TRAIL.Bortezomib, a proteasome inhibitor approved clinically for multiple myeloma
and mantle cell lymphoma, has been investigated intensively for many types of
cancer (9). Accumulating
studies indicate that the combination of bortezomib and TRAIL overcomes the
resistance to TRAIL in various types of cancer, including acute myeloid
leukemia (4), lymphoma
(10–13),
prostate
(14–17),
colon (15,
18,
19), bladder
(14,
16), renal cell carcinoma
(20), thyroid
(21), ovary
(22), non-small cell lung
(23,
24), sarcoma
(25), and HCC
(26,
27). Molecular targets
responsible for the sensitizing effect of bortezomib on TRAIL-induced cell
death include DR4 (14,
27), DR5
(14,
20,
22–23,
28), c-FLIP
(4,
11,
21–23,
29), NF-κB
(12,
24,
30), p21
(16,
21,
25), and p27
(25). In addition, Bcl-2
family also plays a role in the combinational effect of bortezomib and TRAIL,
including Bcl-2 (10,
21), Bax
(13,
22), Bak
(27), Bcl-xL
(21), Bik
(18), and Bim
(15).Recently, we have reported that Akt signaling is a major molecular
determinant in bortezomib-induced apoptosis in HCC cells
(31). In this study, we
demonstrated that bortezomib overcame TRAIL resistance in HCC cells through
inhibition of the PI3K/Akt pathway. 相似文献
18.
Lilly Y. W. Bourguignon Weiliang Xia Gabriel Wong 《The Journal of biological chemistry》2009,284(5):2657-2671
19.
20.
Andrés Norambuena Claudia Metz Lucas Vicu?a Antonia Silva Evelyn Pardo Claudia Oyanadel Loreto Massardo Alfonso González Andrea Soza 《The Journal of biological chemistry》2009,284(19):12670-12679
Galectins have been implicated in T cell homeostasis playing complementary
pro-apoptotic roles. Here we show that galectin-8 (Gal-8) is a potent
pro-apoptotic agent in Jurkat T cells inducing a complex phospholipase
D/phosphatidic acid signaling pathway that has not been reported for any
galectin before. Gal-8 increases phosphatidic signaling, which enhances the
activity of both ERK1/2 and type 4 phosphodiesterases (PDE4), with a
subsequent decrease in basal protein kinase A activity. Strikingly, rolipram
inhibition of PDE4 decreases ERK1/2 activity. Thus Gal-8-induced PDE4
activation releases a negative influence of cAMP/protein kinase A on ERK1/2.
The resulting strong ERK1/2 activation leads to expression of the death factor
Fas ligand and caspase-mediated apoptosis. Several conditions that decrease
ERK1/2 activity also decrease apoptosis, such as anti-Fas ligand blocking
antibodies. In addition, experiments with freshly isolated human peripheral
blood mononuclear cells, previously stimulated with anti-CD3 and anti-CD28,
show that Gal-8 is pro-apoptotic on activated T cells, most likely on a
subpopulation of them. Anti-Gal-8 autoantibodies from patients with systemic
lupus erythematosus block the apoptotic effect of Gal-8. These results
implicate Gal-8 as a novel T cell suppressive factor, which can be
counterbalanced by function-blocking autoantibodies in autoimmunity.Glycan-binding proteins of the galectin family have been increasingly
studied as regulators of the immune response and potential therapeutic agents
for autoimmune disorders (1).
To date, 15 galectins have been identified and classified according with the
structural organization of their distinctive monomeric or dimeric carbohydrate
recognition domain for β-galactosides
(2,
3). Galectins are secreted by
unconventional mechanisms and once outside the cells bind to and cross-link
multiple glycoconjugates both at the cell surface and at the extracellular
matrix, modulating processes as diverse as cell adhesion, migration,
proliferation, differentiation, and apoptosis
(4–10).
Several galectins have been involved in T cell homeostasis because of their
capability to kill thymocytes, activated T cells, and T cell lines
(11–16).
Pro-apoptotic galectins might contribute to shape the T cell repertoire in the
thymus by negative selection, restrict the immune response by eliminating
activated T cells at the periphery
(1), and help cancer cells to
escape the immune system by eliminating cancer-infiltrating T cells
(17). They have also a
promising therapeutic potential to eliminate abnormally activated T cells and
inflammatory cells (1). Studies
on the mostly explored galectins, Gal-1, -3, and -9
(14,
15,
18–20),
as well as in Gal-2 (13),
suggest immunosuppressive complementary roles inducing different pathways to
apoptosis. Galectin-8
(Gal-8)4 is one of the
most widely expressed galectins in human tissues
(21,
22) and cancerous cells
(23,
24). Depending on the cell
context and mode of presentation, either as soluble stimulus or extracellular
matrix, Gal-8 can promote cell adhesion, spreading, growth, and apoptosis
(6,
7,
9,
10,
22,
25). Its role has been mostly
studied in relation to tumor malignancy
(23,
24). However, there is some
evidence regarding a role for Gal-8 in T cell homeostasis and autoimmune or
inflammatory disorders. For instance, the intrathymic expression and
pro-apoptotic effect of Gal-8 upon CD4highCD8high
thymocytes suggest a role for Gal-8 in shaping the T cell repertoire
(16). Gal-8 could also
modulate the inflammatory function of neutrophils
(26), Moreover Gal-8-blocking
agents have been detected in chronic autoimmune disorders
(10,
27,
28). In rheumatoid arthritis,
Gal-8 has an anti-inflammatory action, promoting apoptosis of synovial fluid
cells, but can be counteracted by a specific rheumatoid version of CD44
(CD44vRA) (27). In systemic
lupus erythematosus (SLE), a prototypic autoimmune disease, we recently
described function-blocking autoantibodies against Gal-8
(10,
28). Thus it is important to
define the role of Gal-8 and the influence of anti-Gal-8 autoantibodies in
immune cells.In Jurkat T cells, we previously reported that Gal-8 interacts with
specific integrins, such as α1β1, α3β1, and
α5β1 but not α4β1, and as a matrix protein promotes cell
adhesion and asymmetric spreading through activation of the extracellular
signal-regulated kinases 1 and 2 (ERK1/2)
(10). These early effects
occur within 5–30 min. However, ERK1/2 signaling supports long term
processes such as T cell survival or death, depending on the moment of the
immune response. During T cell activation, ERK1/2 contributes to enhance the
expression of interleukin-2 (IL-2) required for T cell clonal expansion
(29). It also supports T cell
survival against pro-apoptotic Fas ligand (FasL) produced by themselves and by
other previously activated T cells
(30,
31). Later on, ERK1/2 is
required for activation-induced cell death, which controls the extension of
the immune response by eliminating recently activated and restimulated T cells
(32,
33). In activation-induced
cell death, ERK1/2 signaling contributes to enhance the expression of FasL and
its receptor Fas/CD95 (32,
33), which constitute a
preponderant pro-apoptotic system in T cells
(34). Here, we ask whether
Gal-8 is able to modulate the intensity of ERK1/2 signaling enough to
participate in long term processes involved in T cell homeostasis.The functional integration of ERK1/2 and PKA signaling
(35) deserves special
attention. cAMP/PKA signaling plays an immunosuppressive role in T cells
(36) and is altered in SLE
(37). Phosphodiesterases
(PDEs) that degrade cAMP release the immunosuppressive action of cAMP/PKA
during T cell activation (38,
39). PKA has been described to
control the activity of ERK1/2 either positively or negatively in different
cells and processes (35). A
little explored integration among ERK1/2 and PKA occurs via phosphatidic acid
(PA) and PDE signaling. Several stimuli activate phospholipase D (PLD) that
hydrolyzes phosphatidylcholine into PA and choline. Such PLD-generated PA
plays roles in signaling interacting with a variety of targeting proteins that
bear PA-binding domains (40).
In this way PA recruits Raf-1 to the plasma membrane
(41). It is also converted by
phosphatidic acid phosphohydrolase (PAP) activity into diacylglycerol (DAG),
which among other functions, recruits and activates the GTPase Ras
(42). Both Ras and Raf-1 are
upstream elements of the ERK1/2 activation pathway
(43). In addition, PA binds to
and activates PDEs of the type 4 subfamily (PDE4s) leading to decreased cAMP
levels and PKA down-regulation
(44). The regulation and role
of PA-mediated control of ERK1/2 and PKA remain relatively unknown in T cell
homeostasis, because it is also unknown whether galectins stimulate the PLD/PA
pathway.Here we found that Gal-8 induces apoptosis in Jurkat T cells by triggering
cross-talk between PKA and ERK1/2 pathways mediated by PLD-generated PA. Our
results for the first time show that a galectin increases the PA levels,
down-regulates the cAMP/PKA system by enhancing rolipram-sensitive PDE
activity, and induces an ERK1/2-dependent expression of the pro-apoptotic
factor FasL. The enhanced PDE activity induced by Gal-8 is required for the
activation of ERK1/2 that finally leads to apoptosis. Gal-8 also induces
apoptosis in human peripheral blood mononuclear cells (PBMC), especially after
activating T cells with anti-CD3/CD28. Therefore, Gal-8 shares with other
galectins the property of killing activated T cells contributing to the T cell
homeostasis. The pathway involves a particularly integrated signaling context,
engaging PLD/PA, cAMP/PKA, and ERK1/2, which so far has not been reported for
galectins. The pro-apoptotic function of Gal-8 also seems to be unique in its
susceptibility to inhibition by anti-Gal-8 autoantibodies. 相似文献